Solid Biosciences is trading at $7.52, down 6.23%, primarily amid biotech-sector weakness.
- XBI is down 2.04% amid broader market selling; higher crude oil prices and Treasury yields are pressuring growth-oriented healthcare stocks.
- No verified company-specific announcement, FDA action, earnings release, or clinical update was identified for September 24, 2026; the latest investor-relations release was dated September 2.
- The decline follows a 10.09% drop to $8.02 on September 23, while broader indexes are also lower.